Literature DB >> 29335258

Cleavage of TL1A Differentially Regulates Its Effects on Innate and Adaptive Immune Cells.

John R Ferdinand1,2, Arianne C Richard1,3,4, Françoise Meylan1, Aymen Al-Shamkhani2, Richard M Siegel5.   

Abstract

TNF superfamily cytokines play major roles in the regulation of adaptive and innate immunity. The TNF superfamily cytokine TL1A (TNFSF15), through its cognate receptor DR3 (TNFRSF25), promotes T cell immunity to pathogens and directly costimulates group 2 and 3 innate lymphoid cells. Polymorphisms in the TNFSF15 gene are associated with the risk for various human diseases, including inflammatory bowel disease. Like other cytokines in the TNF superfamily, TL1A is synthesized as a type II transmembrane protein and cleaved from the plasma membrane by metalloproteinases. Membrane cleavage has been shown to alter or abrogate certain activities of other TNF family cytokines; however, the functional capabilities of membrane-bound and soluble forms TL1A are not known. Constitutive expression of TL1A in transgenic mice results in expansion of activated T cells and promotes intestinal hyperplasia and inflammation through stimulation of group 2 innate lymphoid cells. Through the generation of membrane-restricted TL1A-transgenic mice, we demonstrate that membrane TL1A promotes expression of inflammatory cytokines in the lung, dependent upon DR3 expression on T cells. Soluble TL1A alone was unable to produce this phenotype but was still able to induce intestinal type 2 inflammation independently of T cells. These data suggest differential roles for membrane and soluble TL1A on adaptive and innate immune cells and have implications for the consequences of blocking these two forms of TL1A.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29335258      PMCID: PMC5812441          DOI: 10.4049/jimmunol.1700891

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.

Authors:  Thi Sau Migone; Jun Zhang; Xia Luo; Li Zhuang; Cecil Chen; Bugen Hu; June S Hong; James W Perry; Su Fang Chen; Joe X H Zhou; Yun Hee Cho; Stephen Ullrich; Palanisamy Kanakaraj; Jeffrey Carrell; Ernest Boyd; Henrik S Olsen; Gang Hu; Laurie Pukac; Ding Liu; Jian Ni; Sunghee Kim; Reiner Gentz; Ping Feng; Paul A Moore; Steve M Ruben; Ping Wei
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

2.  The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells.

Authors:  John L Prehn; Lisa S Thomas; Carol J Landers; Qi T Yu; Kathrin S Michelsen; Stephan R Targan
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

3.  Triggering of TNFRSF25 promotes CD8⁺ T-cell responses and anti-tumor immunity.

Authors:  Tomasz J Slebioda; Tania F Rowley; John R Ferdinand; Jane E Willoughby; Sarah L Buchan; Vadim Y Taraban; Aymen Al-Shamkhani
Journal:  Eur J Immunol       Date:  2011-08-04       Impact factor: 5.532

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 5.  The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases.

Authors:  Spyros I Siakavellas; Petros P Sfikakis; Giorgos Bamias
Journal:  Semin Arthritis Rheum       Date:  2015-02-20       Impact factor: 5.532

6.  Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis.

Authors:  David Q Shih; Robert Barrett; Xiaolan Zhang; Nicole Yeager; Hon Wai Koon; Piangwarin Phaosawasdi; Yahui Song; Brian Ko; Michelle H Wong; Kathrin S Michelsen; Gislaine Martins; Charalabos Pothoulakis; Stephan R Targan
Journal:  PLoS One       Date:  2011-01-11       Impact factor: 3.240

7.  Soluble TL1A is sufficient for activation of death receptor 3.

Authors:  Sebastian Bittner; Gertrud Knoll; Simone Füllsack; Maria Kurz; Harald Wajant; Martin Ehrenschwender
Journal:  FEBS J       Date:  2015-11-24       Impact factor: 5.542

8.  The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation.

Authors:  F Meylan; Y-J Song; I Fuss; S Villarreal; E Kahle; I-J Malm; K Acharya; H L Ramos; L Lo; M M Mentink-Kane; T A Wynn; T-S Migone; W Strober; R M Siegel
Journal:  Mucosal Immunol       Date:  2010-10-27       Impact factor: 7.313

9.  The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis.

Authors:  Melanie Jane Bull; Anwen Siân Williams; Zarabeth Mecklenburgh; Claudia Jane Calder; Jason Peter Twohig; Carole Elford; Bronwen Alice James Evans; Tania F Rowley; Tomasz J Slebioda; Vadim Y Taraban; Aymen Al-Shamkhani; Eddie Chung Yern Wang
Journal:  J Exp Med       Date:  2008-09-29       Impact factor: 14.307

10.  The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells.

Authors:  F Meylan; E T Hawley; L Barron; J L Barlow; P Penumetcha; M Pelletier; G Sciumè; A C Richard; E T Hayes; J Gomez-Rodriguez; X Chen; W E Paul; T A Wynn; A N J McKenzie; R M Siegel
Journal:  Mucosal Immunol       Date:  2013-12-25       Impact factor: 7.313

View more
  2 in total

Review 1.  TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.

Authors:  Vassilis Valatas; George Kolios; Giorgos Bamias
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

Review 2.  Crosstalk between epithelium, myeloid and innate lymphoid cells during gut homeostasis and disease.

Authors:  Sonia Ghilas; Ryan O'Keefe; Lisa Anna Mielke; Dinesh Raghu; Michael Buchert; Matthias Ernst
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.